Abbott India Limited - Asset Resilience Ratio
Abbott India Limited (ABBOTINDIA) has an Asset Resilience Ratio of 53.22% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Abbott India Limited (ABBOTINDIA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2005–2025)
This chart shows how Abbott India Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Abbott India Limited.
Liquid Assets Composition Over Time
This chart breaks down Abbott India Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Abbott India Limited to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs12.79 Billion | 22.46% |
| Short-term Investments | Rs17.51 Billion | 30.75% |
| Total Liquid Assets | Rs30.30 Billion | 53.22% |
Asset Resilience Insights
- Very High Liquidity: Abbott India Limited maintains exceptional liquid asset reserves at 53.22% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Abbott India Limited Industry Peers by Asset Resilience Ratio
Compare Abbott India Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Abbott India Limited (2005–2025)
The table below shows the annual Asset Resilience Ratio data for Abbott India Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 51.26% | Rs30.33 Billion ≈ $328.01 Million |
Rs59.17 Billion ≈ $639.93 Million |
+12.66pp |
| 2024-03-31 | 38.59% | Rs20.04 Billion ≈ $216.75 Million |
Rs51.93 Billion ≈ $561.66 Million |
-2.24pp |
| 2023-03-31 | 40.83% | Rs18.60 Billion ≈ $201.18 Million |
Rs45.56 Billion ≈ $492.66 Million |
-22.31pp |
| 2022-03-31 | 63.15% | Rs26.67 Billion ≈ $288.48 Million |
Rs42.24 Billion ≈ $456.82 Million |
+2.00pp |
| 2020-03-31 | 61.14% | Rs21.69 Billion ≈ $234.53 Million |
Rs35.47 Billion ≈ $383.58 Million |
+7.69pp |
| 2019-03-31 | 53.46% | Rs15.72 Billion ≈ $170.01 Million |
Rs29.41 Billion ≈ $318.05 Million |
+12.59pp |
| 2018-03-31 | 40.86% | Rs9.87 Billion ≈ $106.78 Million |
Rs24.16 Billion ≈ $261.30 Million |
-11.65pp |
| 2017-03-31 | 52.51% | Rs10.85 Billion ≈ $117.32 Million |
Rs20.66 Billion ≈ $223.41 Million |
+9.48pp |
| 2016-03-31 | 43.03% | Rs6.96 Billion ≈ $75.23 Million |
Rs16.17 Billion ≈ $174.82 Million |
-0.04pp |
| 2015-03-31 | 43.07% | Rs5.92 Billion ≈ $63.99 Million |
Rs13.74 Billion ≈ $148.55 Million |
+19.96pp |
| 2013-03-31 | 23.11% | Rs2.10 Billion ≈ $22.67 Million |
Rs9.07 Billion ≈ $98.10 Million |
+4.93pp |
| 2012-03-31 | 18.18% | Rs1.46 Billion ≈ $15.74 Million |
Rs8.00 Billion ≈ $86.54 Million |
+13.97pp |
| 2011-03-31 | 4.22% | Rs192.81 Million ≈ $2.09 Million |
Rs4.57 Billion ≈ $49.46 Million |
+0.06pp |
| 2010-03-31 | 4.15% | Rs161.22 Million ≈ $1.74 Million |
Rs3.88 Billion ≈ $41.97 Million |
+0.97pp |
| 2009-03-31 | 3.19% | Rs111.80 Million ≈ $1.21 Million |
Rs3.51 Billion ≈ $37.91 Million |
-0.05pp |
| 2008-03-31 | 3.24% | Rs107.00 Million ≈ $1.16 Million |
Rs3.30 Billion ≈ $35.73 Million |
-0.53pp |
| 2007-03-31 | 3.77% | Rs128.30 Million ≈ $1.39 Million |
Rs3.40 Billion ≈ $36.82 Million |
-0.20pp |
| 2006-03-31 | 3.97% | Rs123.30 Million ≈ $1.33 Million |
Rs3.10 Billion ≈ $33.57 Million |
+1.77pp |
| 2005-03-31 | 2.21% | Rs68.90 Million ≈ $745.13K |
Rs3.12 Billion ≈ $33.75 Million |
-- |
About Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, … Read more